If You Invested in Inari Medical, Inc. (NARI)

Inari Medical, Inc. (NASDAQ: NARI) is a medical device company in the surgical and medical instrument manufacturing industry. According to its public communications, Inari describes its mission as treating and transforming the lives of patients suffering from venous and other vascular diseases. The company is associated with the manufacturing sector and its stock trades on the NASDAQ exchange under the symbol NARI.

Inari states that its ethos is guided by three core principles: "Patients first. No small plans. Take care of each other." These principles frame the company’s approach to developing medical technologies and to supporting physicians and healthcare systems that manage venous thromboembolism and related vascular conditions. Inari emphasizes a focus on unmet and underserved health needs and on improving patient outcomes.

Business focus and disease areas

Inari describes itself as a medical device company with a mission to establish its treatments as the standard of care for venous thromboembolism and four other targeted disease states. Across its public statements, the company repeatedly highlights venous and other vascular diseases as its primary area of focus. Inari also notes that it operates in large, underserved vascular markets, reflecting its emphasis on conditions where existing treatment options may be limited or suboptimal.

The company references a portfolio of purpose-built tools and solutions aimed at thrombus removal and treatment of venous and other vascular diseases. Inari’s communications refer to its work in mechanical thrombectomy and venous interventions, including products that are used in deep vein thrombosis (DVT) and pulmonary embolism (PE). The company has stated that it is passionate about advancing care in these areas and about building treatments that can become standards of care.

Examples of Inari technologies mentioned in public materials

Inari’s news releases describe several named systems and technologies:

• ClotTriever Thrombectomy System – Inari reports that this system is used for thrombus removal in patients suffering from deep vein thrombosis. The company notes that ClotTriever has a mechanism of action designed for complete, wall-to-wall thrombus removal in DVT patients, and that it has been supported by clinical data showing safety and efficacy in removing various types of thrombi. Inari states that ClotTriever is 510(k)-cleared by the U.S. Food and Drug Administration (FDA) and CE-marked for treatment of DVT.
• FlowTriever System – Inari describes FlowTriever as a thrombectomy system used for the treatment of pulmonary embolism and clot in transit in the right atrium. The company states that FlowTriever is 510(k)-cleared by the FDA and CE Mark approved for these indications. Inari highlights FlowTriever in connection with a randomized controlled trial evaluating its performance in intermediate-risk pulmonary embolism.

Inari also refers to its broader portfolio of purpose-built solutions for venous and other vascular diseases, though detailed product lists beyond these named systems are not provided in the available materials.

Clinical research and evidence generation

Inari emphasizes clinical research as a core part of its strategy. The company notes that it leverages capabilities in clinical research, education, and program development to improve patient outcomes. Several large clinical efforts are described in its public news:

• CLOUT Registry – Inari references the 500-patient ClotTriever CLOUT Registry, which evaluates outcomes following mechanical thrombectomy for DVT. The company notes that interim and two-year outcomes from this registry have shown a strong safety profile, significant clot removal, and low rates of post-thrombotic syndrome. It also states that more than 75,000 procedures have been conducted with ClotTriever globally and characterizes ClotTriever as the most studied thrombectomy device for DVT, including ongoing randomized controlled research.
• DEFIANCE Study – Inari describes DEFIANCE as a randomized controlled trial comparing ClotTriever mechanical thrombectomy to anticoagulation alone in patients with DVT. The company notes that this study is designed to evaluate outcomes such as clot removal and clinical results in iliofemoral DVT.
• PEERLESS Randomized Controlled Trial – Inari reports positive results from PEERLESS, a randomized controlled trial comparing FlowTriever to catheter-directed thrombolytics (CDT) in intermediate-risk pulmonary embolism. According to the company, PEERLESS met its primary composite endpoint and showed that FlowTriever patients experienced fewer clinical deteriorations or therapy escalations, fewer intensive care unit (ICU) admissions, shorter ICU stays, faster recovery of clinical symptoms and hemodynamics, shorter hospital stays, and fewer 30-day readmissions compared to CDT. Inari highlights that PEERLESS is the first major randomized PE study in over a decade and that the results were presented at a major cardiology symposium and published in a peer-reviewed journal.

Inari characterizes its research efforts as practice- and guideline-changing and refers to a “golden age of PE research,” positioning its trials as important for informing optimal treatment decisions in venous and pulmonary embolism care.

Geographic and commercial expansion

Inari’s public communications describe several initiatives aimed at expanding access to its technologies. The company reports that it operates in global markets and references commercial expansion outside the United States. In particular, Inari notes:

• Japan – Inari states that it received national reimbursement approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) for the ClotTriever Thrombectomy System for DVT, following prior regulatory approval by the Pharmaceuticals and Medical Devices Agency (PMDA). The company explains that MHLW created a new functional category for ClotTriever, separate from other catheter-based therapies, and that this category carries a reimbursement premium based on clinical data demonstrating safety and efficacy. Inari also reports that it entered into a distribution agreement with Medikit Co., Ltd., a vascular medical device manufacturer, to commercialize ClotTriever in Japan and to support a post-market surveillance study and broader commercial expansion.
• Greater China – Inari describes a joint venture with 6 Dimensions Capital, its successor fund 120 Capital, and VFLO Medical to provide access to Inari’s technologies for patients with unmet needs in Greater China. According to the company, the joint venture allows Inari to commercialize its devices through VFLO’s infrastructure, local relationships, and commercial expertise. VFLO is described as having the right to use Inari’s technology to manufacture products for domestic sale in Greater China.

Inari also references global commercial expansion and the opening of new accounts in its financial communications, indicating that it is broadening the reach of its venous and vascular disease treatments.

Corporate development and financial context

Inari’s public financial disclosures describe its activities as a medical device company generating revenue from its portfolio of venous and vascular disease treatments. The company notes that growth has been driven by expansion of sales territories, opening of new accounts, increased adoption of its procedures, global commercial expansion, and introduction of new products. Inari also references an acquisition of LimFlow and related intangible assets and contingent consideration, indicating involvement in corporate development to expand its capabilities.

Inari uses both GAAP and non-GAAP financial measures in its reporting and provides explanations of non-GAAP operating income (loss), including adjustments for amortization of acquired intangible assets, acquisition-related costs, fair value adjustments to contingent consideration, and capitalized software impairment and related costs. These details reflect how the company presents its operating performance and cost structure to investors.

Engagement with the healthcare and investor community

Inari regularly participates in major healthcare and investor conferences. The company has announced presentations at events such as the J.P. Morgan Healthcare Conference and the Jefferies London Healthcare Conference, as well as analyst and investor meetings aligned with key clinical trial presentations. These activities indicate that Inari engages with both clinical and financial audiences to discuss its research, products, and business strategy.

In its public materials, Inari states that it leverages education and program development alongside clinical research. This suggests a focus on supporting physicians and healthcare systems in adopting its venous and vascular disease treatments and on sharing evidence from its clinical programs.

Company identity and guiding principles

Across multiple communications, Inari reiterates its guiding principles and mission. The company emphasizes that it is committed to improving lives in extraordinary ways, particularly for patients with unmet or underserved health needs in venous thromboembolism and other targeted disease states. It highlights a culture that prioritizes patients, embraces ambitious goals, and encourages care for colleagues.

Inari also notes that it is "just getting started" in its efforts to establish its treatments as standards of care. This language underscores the company’s focus on long-term development of venous and vascular disease therapies and on continued research and commercial expansion.

Position within the medical device industry

Inari operates within the surgical and medical instrument manufacturing industry, with a specific focus on devices and systems for venous and other vascular diseases. The company’s activities include developing and commercializing thrombectomy systems and related technologies, generating clinical evidence through registries and randomized controlled trials, and expanding access to its treatments through partnerships and joint ventures in international markets.

According to its own descriptions, Inari’s work centers on mechanical thrombectomy and venous interventions, particularly in deep vein thrombosis and pulmonary embolism. Its emphasis on clinical research, reimbursement approvals, and international collaborations reflects a strategy focused on both technological development and integration into healthcare systems worldwide.